Revista Cubana de Medicina Militar
ISSN 1561-3046
AROCHE APORTELA, Ronald et al. Paclitaxel eluting stents versus bare metal stents restenosis. []. , 51, 1 01--2022. ISSN 1561-3046.
Introduction:
The restenosis of the paclitaxel-eluting stents used in Cuba has not been studied.
Objective:
To evaluate the restenosis of paclitaxel-eluting stents and conventional stents.
Methods:
64 patients with stent restenosis were included, from a previous prospective study; in 318 patients followed up for 3 years after percutaneous coronary intervention; 25 with a paclitaxel-eluting stent and 39 conventional metal stent. Restenosis was considered as a new lesion ≥ 50 % of the vessel lumen with proven ischemia. The time to onset, angiographic pattern and alternative revascularization were described.
Results:
Restenosis in the group with paclitaxel-eluting stents was 15.7 % with a mean survival time without restenosis of 32.4 months vs. 24.5 % in conventional stents, with restenosis-free survival of 29.8 months, (p = 0.047). In the group with paclitaxel-eluting stents, the IB pattern predominated (30.3 %) and the conventional stent III (28.3 %). In 28.0 % of the paclitaxel-eluting stent group, revascularization surgery was used vs. 5.1 % in the conventional stent group.
Conclusions:
The paclitaxel-eluting stent achieves a superior and more durable restenosis-free survival than the conventional stent. Restenosis in paclitaxel-eluting stents is focal, with a higher frequency of revascularization by surgery, and in conventional stents it is mostly diffuse.
: stent restenosis; paclitaxel; drug eluting stent.